Next in Care: Why AI Healthcare Infrastructure Is Becoming the Real Market Battle
Next in Care during Tech Week by a16z brings together HSBC Innovation Banking, Jorge Conde, Eric Kelsic, and Katherine Andersen to examine how AI is reshaping healthcare infrastructure, biotech, and investment strategy.
Healthcare has officially entered the uncomfortable middle phase of the AI cycle. Everybody says artificial intelligence with the confidence of a televangelist selling certainty, yet most hospital systems still operate like a filing cabinet survived a cyberattack and got promoted to enterprise software. The ambition is futuristic while the infrastructure still wheezes like it climbed stairs too fast. That tension is exactly why “Next in Care: How AI is Reshaping Healthcare” matters before it even happens. The event, hosted by HSBC Innovation Banking and Andreessen Horowitz (a16z), during Tech Week by a16z in Boston, arrives at a moment when healthcare, biotech, venture capital, and enterprise AI are colliding into the same economic conversation.
The gathering brings together Jorge Conde, General Partner at a16z; Eric Kelsic, CEO of Dyno Therapeutics; and Katherine Andersen, Head of Life Sciences and Healthcare at HSBC Innovation Banking. This is not another AI networking event stuffed with recycled talking points and founders pretending their chatbot can cure operational decay. The significance here is structural. Healthcare is moving from digitization into intelligence infrastructure. Investors know it. Operators feel it. Regulators are bracing for it. The market is now trying to determine which companies are building real systems versus polished hallucinations wrapped in premium branding.
About Next in Care
“Next in Care: How AI is Reshaping Healthcare” is positioned as a private, curated discussion during Tech Week by a16z in Boston. The format matters almost as much as the speakers because restricted-access healthcare events tend to attract operators closer to implementation than performance. Less conference cosplay. More people carrying actual accountability. That distinction matters because healthcare AI has entered a credibility phase. The first wave of excitement rewarded anybody capable of placing “AI-powered” inside a funding deck. The second phase is much less forgiving as health systems now want operational outcomes, investors want evidence, and enterprise buyers want implementation without regulatory catastrophe.
About Next in Care
“Next in Care: How AI is Reshaping Healthcare” is positioned as a private, curated discussion during Tech Week by a16z in Boston. The format matters almost as much as the speakers because restricted-access healthcare events tend to attract operators closer to implementation than performance. Less conference cosplay. More people carrying actual accountability. That distinction matters because healthcare AI has entered a credibility phase. The first wave of excitement rewarded anybody capable of placing “AI-powered” inside a funding deck. The second phase is much less forgiving as health systems now want operational outcomes, investors want evidence, and enterprise buyers want implementation without regulatory catastrophe.
Founders are discovering that healthcare workflows do not care about product-market-fit slogans if integration breaks reimbursement models or compliance structures. The room reflects that transition. HSBC Innovation Banking sits directly inside the financial architecture supporting healthcare growth companies while Andreessen Horowitz continues expanding its influence across healthcare infrastructure, biotech, AI, and enterprise software. Tech Week by a16z arriving in Boston signals something broader about where institutional attention is moving geographically and strategically because Boston has always understood the chemistry between academia, biotech, capital, and technical talent. The city does not romanticize innovation. It industrializes it.
Why This Matters Right Now
AI healthcare conversations have become noisy because too many companies are selling acceleration without acknowledging complexity. Healthcare is not consumer software. A missed recommendation does not create a minor inconvenience. It can create litigation, financial exposure, operational failure, or patient harm. That reality is reshaping investor behavior across healthcare AI, biotech infrastructure, diagnostics, and automation platforms as sophisticated operators now ask harder questions around whether AI can reduce administrative burden without increasing regulatory risk or improve drug discovery economics in a meaningful way.
They also want to know whether healthcare systems can integrate intelligence layers without destroying workflow continuity and whether AI can move from productivity theater into actual infrastructure. Those questions sit directly underneath the significance of “Next in Care.” The event represents a broader market transition from AI experimentation toward AI accountability, which is where companies like Dyno Therapeutics become strategically important.
Why Dyno Therapeutics and Eric Kelsic Matter
Dyno Therapeutics operates at the intersection of artificial intelligence and genetic medicine, which sounds futuristic until you realize the healthcare market desperately needs computational efficiency inside biological research and delivery systems. Eric Kelsic represents a category of biotech operator increasingly shaping the market: technically credible founders building infrastructure instead of narrative inflation. That distinction matters because biotech and healthcare investors have spent years funding companies promising platform transformation while quietly hoping operational execution catches up before the capital runs out.
The AI cycle has intensified that pressure. Now every biotech company wants computational leverage, every healthcare platform wants predictive capability, and every investor wants exposure without getting trapped inside speculative vapor. Dyno Therapeutics reflects a larger shift toward AI-guided biological engineering, where machine learning is no longer treated as a marketing layer but as a core research and development mechanism. That changes the economics of healthcare innovation.
The Bigger Signal Around Tech Week by a16z
Tech Week by a16z coming to Boston is not just another city expansion. It reflects the growing overlap between enterprise AI, healthcare infrastructure, venture capital, cybersecurity, biotech, and institutional capital markets. The modern technology economy is consolidating around infrastructure conversations again. Not social growth hacks. Not vanity metrics. Infrastructure. Healthcare sits directly inside that transition because the industry remains one of the largest, slowest, and most operationally expensive systems in the global economy.
AI companies see opportunity there for the same reason Wall Street notices inefficiency because friction eventually attracts capital. But healthcare is also where hype gets exposed fastest. A consumer app can survive mediocre execution while healthcare infrastructure cannot. That is why rooms like “Next in Care” matter before the event even starts. The people attending are not simply looking for optimism. They are trying to understand where durable value is forming across healthcare AI, biotech, operational systems, and investment strategy. The conversation is no longer whether AI enters healthcare. The conversation is who survives once intelligence becomes operational infrastructure instead of experimental software.
Frequently Asked Questions
What is “Next in Care: How AI is Reshaping Healthcare”?
“Next in Care” is a healthcare AI discussion hosted during Tech Week by a16z in Boston by HSBC Innovation Banking and Andreessen Horowitz.
Who are the featured speakers at Next in Care?
The confirmed speakers are Jorge Conde of a16z, Eric Kelsic of Dyno Therapeutics, and Katherine Andersen of HSBC Innovation Banking.
Why does this healthcare AI event matter?
The event reflects growing institutional focus on AI infrastructure across healthcare, biotech, diagnostics, and operational systems.
What is Dyno Therapeutics?
Dyno Therapeutics is a biotechnology company focused on applying artificial intelligence to genetic medicine and delivery system development.
Why is Boston important for healthcare and AI?
Boston combines biotech research, venture capital, academic institutions, healthcare systems, and technical talent into one concentrated innovation ecosystem.
What does this event signal about the healthcare market?
The event signals a shift from AI experimentation toward operational healthcare infrastructure and investment accountability.